Dr. Reddy’s Laboratories is currently trading at Rs. 2667.05, up by 65.35 points or 2.51% from its previous closing of Rs. 2601.70 on the BSE.
The scrip opened at Rs. 2620.00 and has touched a high and low of Rs. 2675.80 and Rs. 2620.00 respectively. So far 13573 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.
Last one week high and low of the scrip stood at Rs. 2675.80 and Rs. 2514.00 respectively. The current market cap of the company is Rs. 44384.79 crore.
The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 44.50% and 14.44% respectively.
Dr. Reddy's Laboratories has launched Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban (Bupropion Hydrochloride) Extended-Release Tablets, approved by the US Food and Drug Administration (USFDA).
The Zyban brand and generic had US sales of approximately $5.4 million MAT for the most recent twelve months ending in June 2019 according to IQVIA Health. Dr. Reddy's Bupropion Hydrochloride Extended-Release Tablets, USP (SR) are available as 150 mg dosage strength in bottle count sizes of 60.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.